{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:37:25Z","timestamp":1784824645606,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40257-025-00922-2","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:04:06Z","timestamp":1738627446000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-5961","authenticated-orcid":false,"given":"Siddhartha","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim","family":"Abduelmula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Georgakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalad","family":"Maliyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bagit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernejoy","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alim R.","family":"Devani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-5515","authenticated-orcid":false,"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"11","key":"922_CR1","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101\u201312. https:\/\/doi.org\/10.1111\/jdv.18409.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"922_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2024.04.027","volume":"91","author":"A Rimke","year":"2024","unstructured":"Rimke A, Sood S, Rankin BD, et al. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 16-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(2):359\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.027.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"922_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2024.05.085","volume":"91","author":"S Sood","year":"2024","unstructured":"Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(5):936\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.085. (Epub 2024 Jun 15 PMID: 38885841).","journal-title":"J Am Acad Dermatol"},{"issue":"10273","key":"922_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. Lancet. 2021;397(10273):475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"issue":"8","key":"922_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jdv.18126","volume":"36","author":"N Loft","year":"2022","unstructured":"Loft N, Egeberg A, Rasmussen MK, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol. 2022;36(8):1284\u201391. https:\/\/doi.org\/10.1111\/jdv.18126.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","volume":"10","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. https:\/\/doi.org\/10.3389\/fmed.2023.1243843.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"922_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2024.01.025","volume":"90","author":"K Papp","year":"2024","unstructured":"Papp K, Prajapati VH, Maari C, Legault M, Barakat M, Vender R. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: a phase 4, multicenter, open-label study. J Am Acad Dermatol. 2024;90(6):1254\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.01.025.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00922-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:26:53Z","timestamp":1740385613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00922-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"12 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mr. Sood, Mr. Rimke, Dr. Rankin, Dr. Abduelmula, Dr. Georgakopoulos, Dr. Maliyar, and Mr. Bagit have no relevant disclosures. Ms. Fernejoy Leung has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Arcutis, Bausch Health, BioScript Solutions, Incyte, Janssen, LEO Pharma, Novartis, and UCB. Dr. Alim R. Devani has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Medexus, Nimbus Lakshmi, Novartis, Pediapharm, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, UCB, and Valeant. Dr. Ronald Vender has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Actelion, Amgen, Aralez, Arcutis, Astellas, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Centocor, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, LEO Pharma, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. Dr. Jensen Yeung has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, Anacor, Arcutis, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Dr. Vimal H. Prajapati has been an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health\/Valeant, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Cipher, Concert, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for AbbVie, AnaptysBio, Arcutis, Arena, Asana, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Regeneron, RAPT Therapeutics, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Internal review board (IRB) approval was obtained by the research ethics boards at each respective academic institution from which data were collected (Sunnybrook Health Sciences Centre [205-2018]; Women\u2019s College Hospital [2018-0079-E]).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Supplemental data are available electronically via Mendeley at: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"V.H.P., J.Y., R.V., and A.R.D. contributed to conceptualization and study design. S.S., A.R., B.D.R., A.A., J.R.G., K.M., A.B., and F.L. contributed to data collection. S.S. contributed to data analysis. S.S., V.H.P., J.Y., and R.V. contributed to initial drafting of the manuscript. All authors contributed to editing and approval of the final draft.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Jensen Yeung is an Editorial Board member of the American Journal of Clinical Dermatology. Professor Yeung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional declarations"}}]}}